Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ACOX2 Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA584673
Description
Immunogen sequence: VTVKGFTEAL EKLENEPAIQ QVLKRLCDLH AIHGILTNSG DFLHDAFLSG AQVDMARTAY LDLLRLIRKD AILLTDAFDF TDQCL.
The product of this gene belongs to the acyl-CoA oxidase family. It encodes the branched-chain acyl-CoA oxidase which is involved in the degradation of long branched fatty acids and bile acid intermediates in peroxisomes. Deficiency of this enzyme results in the accumulation of branched fatty acids and bile acid intermediates, and may lead to Zellweger syndrome, severe mental retardation, and death in children.
Specifications
ACOX2 | |
Polyclonal | |
Unconjugated | |
ACOX2 | |
3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA 24-hydroxylase; 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA oxidase; Acox2; acyl-CoA oxidase 2; acyl-CoA oxidase 2, branched chain; acyl-Coenzyme A oxidase 2, branched chain; BCOX; branched chain acyl-CoA oxidase; BRCACOX; BRCOX; Peroxisomal acyl-coenzyme A oxidase 2; peroxisomal branched chain acyl-CoA oxidase; THCA-CoA oxidase; THCCox; trihydroxycoprostanoyl-CoA oxidase | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
8309 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry, Western Blot | |
0.2 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q99424 | |
ACOX2 | |
Recombinant protein corresponding to Human ACOX2. Recombinant protein control fragment (Product #RP-105345). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction